Unlock the power of BLENREP in combination therapy
- Among patients who experienced an eye-related side effect, 92% (n=120/131) continued treatment on or after the onset of the first event and received a median of 5 additional doses (range: 1 to 21)
- Permanent discontinuation of any component of BPd due to eye-related side effects, including ocular adverse reactions, visual acuity changes, or corneal examination findings, occurred in 11% of patients
| Endpoint | DREAMM-7: BVd vs DVd | DREAMM-8: BPd vs PVd |
|---|---|---|
| Median PFS (95% CI) | 36.6 (28.4–NR) months vs 13.4 (11.1–17.5) months (HR: 0.41; 95% CI: 0.31–0.53; p<0.00001) See PFS data for DREAMM-7 | NR (20.6–NR) vs 12.7 (9.1–18.5) months (HR: 0.52; 95% CI: 0.37–0.73; p<0.001) See PFS data for DREAMM-8 |
| Safety | BLENREP had a well-established safety profile that was generally well tolerated See safety data for DREAMM-7 | BLENREP had a well-established safety profile that was generally well tolerated See safety data for DREAMM-8 |
| ERSE | Eye-related side effects are expected with BLENREP. Dose interruptions and/or dose reductions are required to manage eye-related side effects and other adverse events See ERSE data for DREAMM-7 | Eye-related side effects are expected with BLENREP. Dose interruptions and/or dose reductions are required to manage eye-related side effects and other adverse events See ERSE data for DREAMM-8 |
| Administration | BLENREP is a 30-minute outpatient infusion without hospitalization, pre-medication or monitoring |